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Abstract 
Objective: Asthma often complicates pregnancy and represents a risk for complications. 
Periostin is considered as a biomarker of asthma; however, as it also plays a role in normal 
gestation, pregnancy may influence circulating periostin levels. This is the first study assessing 
periostin in asthmatic pregnancy. 
Methods: Plasma periostin levels were investigated in asthma (asthmatic non-pregnant, ANP; N 
= 19) and asthmatic pregnancy (AP; N = 14), compared to healthy non-pregnant controls (HNP; 
N = 12) and healthy pregnant women (HP; N = 17). The relationship between periostin levels 
and asthma control determinants was also evaluated. The diagnostic efficacy of periostin to 
detect uncontrolled asthma was analyzed using ROC analysis. 
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Results: Plasma periostin levels were similar in the HNP and ANP (55.68 [37.21-67.20] vs. 
45.25 [32.67-64.55], p > 0.05), and elevated in the HP (68.81 [57.34-98.84] ng/mL, p = 0.02 vs. 
HNP) and AP groups (54.02 [44.30-74.94] ng/mL, p = 0.0346 vs. ANP). Periostin levels of the 
two pregnant groups were similar (p > 0.05). In AP women periostin correlated negatively with 
FEV1 (r = -0.5516) and positively with Raw (r = 0.5535; both p < 0.05). 
Conclusions: Pregnancy itself increases circulating periostin levels and this elevation is 
detectable in asthmatic pregnancy as well. Although periostin correlates with lung function in 
asthmatic pregnancy, periostin as a biomarker has to be handled with caution in pregnant patients 
due to the influence of pregnancy on its plasma level. 
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Introduction 
Asthma is a chronic inflammatory disease of the airways characterized by variable and recurrent 
symptoms, local inflammation, reversible airflow obstruction, and bronchospasm [1]. It has a 
high burden of morbidity especially if not controlled which occurs in up to 50% of cases 
worldwide [1]. Asthma is a heterogeneous disease with several phenotypes. Easily obtainable 
blood biomarkers related to uncontrolled disease would help to identify patients at risk and to 
phenotype patients favoring a specific treatment which can help to optimize disease outcome; 
however optimal blood biomarkers are still missing. 
At the same time, asthma is one of the most common chronic diseases complicating pregnancy, 
occurring in 8-12% of all gestations [2]. It represents a risk for potentially serious maternal and 
fetal morbidities, including preterm delivery, gestational hypertension, preeclampsia, low birth 
weight, and neonatal mortality [3, 4]. On the other hand pregnancy may also influence asthma 
control with the deterioration of symptoms in one-third of all asthmatic pregnant women [5]. 
Notably, if the disease is well controlled the risks of poor pregnancy outcomes decrease [6], 
therefore, maintaining optimal control in this period is crucial. Hence in asthmatic pregnancy it 
would be especially important to have clinically usable biomarkers that would indicate the loss 
of asthma control and would thus help to identify asthmatic pregnant women with elevated risk 
of pregnancy complications. Pregnancy itself can influence spirometry results [7], and this 
measurement cannot be performed in all cases because it requires vigorous breathing maneuver. 
Furthermore, the available techniques used to determine specific asthma phenotypes (e.g. 
induced sputum) are semi-invasive hence cannot be used in pregnancy. Fractional exhaled nitric 
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oxide (FENO) measurement is a promising non-invasive method which can be utilized also in 
pregnancy [8], moreover, asthma treatment based on FENO during pregnancy was able to 
decrease the occurrence of exacerbations, together with improving life quality and decreasing 
neonatal hospitalizations compared with traditional asthma management [9]. However, a more 
recent longitudinal study detected large intraindividual variability in asthmatic pregnant women 
independently of asthma control [10]. Furthermore, perception of asthma control is subjective 
and can vary from patient to patient. Therefore circulating, non-invasively obtainable biomarkers 
related to disease control or lung function would largely support clinical decision-making in this 
population. Previously two promising blood biomarkers, suPAR and hyaluronic acid were 
investigated, that were both proven to be usable rather in asthma alone than in asthmatic 
pregnancy [11, 12]. 
In the recent years, periostin has emerged as a valuable biomarker in asthma, primarily in its T 
helper 2 (Th2)-induced, eosinophil-predominant phenotype [13]. Periostin is an extracellular 
matrix protein, which is expressed at low levels in connective tissue and plays a role in 
generation of collagen. Its expression is largely increasing in the presence of tissue injury or 
inflammation, contributing actively to reparatory processes and wound healing [14]. Periostin is 
also involved in Th2-type allergic inflammation [15], as it was demonstrated in atopic dermatitis 
[16] and eosinophilic esophagitis [17]. Periostin is among the most highly differentially 
expressed genes of airway epithelium in asthma [18], and expression of this gene correlates with 
subepithelial fibrosis [19]. Its contribution to airway fibrosis and remodeling is reflected also in 
the clinical setting, as increased periostin level at enrollment was associated with a decline in 
forced expiratory volume in 1 second (FEV1) of 30 mL or greater per year in an 8-year long 
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study [20]. Periostin also facilitates eosinophil infiltration [17], and was shown to be associated 
with airway eosinophilia in a study examining severe asthmatics on high-doses steroid treatment 
[21]; moreover it was proven to be the best single predictor of airway eosinophilia [21]. 
Pathomechanism-based targeted therapy is increasingly important in optimal personalized 
treatment of asthma. In severe asthma periostin already may influence therapeutic decisions 
since it can help to choose patients who will respond to anti-interleukin-(IL-)13 treatment [22] or 
anti IL-5 therapy [23]. Serum periostin levels also correlated with fractional exhaled nitric oxide 
(FENO) and with airway hyperresponsiveness to methacholine and mannitol in asthmatic children 
[24]. More importantly, high serum periostin in patients with high FENO was a risk for 
subsequent asthma exacerbations despite taking high-dose ICS, independent of known risks 
including low FEV1 [25]. Importantly, circulating periostin levels seemed to be stable within 
subjects at 3 measurements in a 5-week period [21]. However, biomarkers used in the non-
pregnant state are not always applicable in the same way in pregnant women and often require 
altered reference ranges, as showed e.g. with D-dimer and fibrinogen [26], the erythrocyte 
sedimentation rate [27] white blood cell counts [28] or C-reactive protein (CRP) levels [29]. 
Circulating periostin level may be altered by gestation itself as it has a role in embryo 
implantation and in maintaining normal pregnancy. It induces endometrial decidualization and 
promotes migration of trophoblastic cells [30, 31]. It is also required for normal embryogenesis 
[32, 33, 34, 35]. Lower periostin levels were detected in decidua, trophoblastic tissues, and sera 
in spontaneous abortion compared to healthy pregnant women undergoing voluntary pregnancy 
termination [36]. On the other hand, serum periostin concentration was further elevated in 
patients with preeclampsia compared with normotensive pregnant women [37]. However, 
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according to our knowledge, there are no data about periostin level or its relationship to asthma 
symptoms in asthmatic pregnancy. 
As circulating periostin level may be influenced by gestation, its usefulness as a biomarker may 
be altered in pregnant patients. The present study investigated circulating periostin level in 
pregnant and non-pregnant subjects with or without asthma, with the main aim to evaluate 
whether pregnancy influences plasma periostin levels in asthmatic patients. The relationship 
between periostin levels and asthma control determinants was also evaluated. In order to have a 
more complete view on the inflammatory state of patients, circulating CRP and interleukin (IL)-6 
levels, together with peripheral eosinophil cell percentages were measured as well. 
Methods 
Ethics Statement 
Written informed consent was obtained from the subjects, and our study was reviewed and 
approved by an independent ethical committee of the institution (Institutional and Regional 
Research Ethics Committee; 7828-4/2014). The study adhered to the tenets of the most recent 
revision of the Declaration of Helsinki. 
Study participants 
The study had a cross-sectional design. 12 healthy non-pregnant (HNP) and 17 healthy pregnant 
(HP) women, and19 asthmatic non-pregnant (ANP) and 14 asthmatic pregnant (AP) women 
were enrolled. Asthmatic patients were assessed at their regular visit at the outpatient clinic. 
They had persistent disease and asthma had been diagnosed according to the current guidelines 
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[1]. Exclusion criteria were current smoking or more than 5 pack years of smoking history in 
order to exclude presence of COPD, any other chronic disease (except for allergic rhinitis), acute 
infection within four weeks of measurement, fetal infection and multi-fetal gestation. Patients 
were asked not to use their medication 12 hours before visits. Healthy pregnant subjects were 
recruited when attending their scheduled visit. Healthy non-pregnant controls were volunteers 
and had a negative history and negative status upon detailed physical and routine laboratory 
examination. 
Measurement of plasma periostin and other circulating markers 
Plasma periostin concentrations were measured with the Human periostin/osteoblast specific 
factor 2 (POSTN) ELISA Kit (MBS705827; MyBioSource, Inc., San Diego, California, USA). 
Plasma was isolated from EDTA anticoagulated blood samples between 3-8°C within 30 minutes 
and stored at −80°C until measurement as recommended by the manufacturer. 
CRP, IL-6 and eosinophil percentages were measured as routine laboratory tests using 
commercially available reagents. CRP values below the level of detection (1 mg/L) were 
regarded as 1 mg/L. IL-6 values below the level of detection (1.5 pg/mL) were regarded as 1.5 
pg/mL. 
Lung function measurements and asthma control evaluation 
Lung function was measured by means of electronic spirometer (PDD-301/s, Piston, Budapest, 
Hungary) according to the American Thoracic Society (ATS) guidelines [38]. Three technically 
acceptable maneuvers were performed and the best was used. Forced expiratory volume in one 
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second (FEV1), peak expiratory flow rate (PEF), airway resistance (Raw) and forced expiratory 
flow at 25--75% of forced vital capacity (FEF25-75%) were recorded. Asthma control was assessed 
using the Asthma Control Test (ACT) recommended by the current asthma guideline [1]. 
Statistics 
Data distribution was analyzed by D’Agostino-Pearson normality test. Comparisons between the 
study groups were made with Kruskal-Wallis and Dunn’s post hoc multiple comparison tests. 
Correlation analyses were performed using Spearman’s test due to non-normal distribution of 
data. Area Under Curve (AUC) values of Receiver Operating Characteristics (ROC) curves were 
calculated using standard methods and data are presented as AUC ROC (95% CI). p values < 
0.05 were considered significant. Sample size of the study was calculated to achieve an 80% 
power to detect 50% (effect size of 0.5) difference among the 4 groups regarding circulating 
periostin levels. 
Statistics was calculated using the Statistica software (version 11, StatSoft, Inc, Tulsa, OK, USA) 
and Graph Pad Prism software 5 (GraphPad Software, La Jolla, CA, USA). Data are expressed as 
median [interquartile range]. 
Results 
Clinical characteristics 
Clinical data and inflammatory parameters of the four study groups are summarized in Table 1. 
The median age of participants was comparable between study groups (p > 0.05). Gestational age 
at blood sampling did not differ between the AP and HP groups (p > 0.05). Although the median 
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of newborns’ birth weight seemed somewhat lower in the asthmatic pregnant group, there was no 
significant difference between either gestational age at delivery (p = 0.43) or fetal birth weight (p 
= 0.19) in the two pregnant groups. 
No difference was detected in the control of asthma or in the prescribed daily dose of inhaled 
corticosteroids (ICS) between the ANP and AP groups (Table 1). However, forced vital capacity 
(FVC; 95.5±10.3 vs. 108.3±11.6% of predicted) and peak expiratory flow (PEF; 77.9±15.8 vs. 
90.9±13.9% of predicted) were lower in the pregnant than in the non-pregnant patients; the other 
lung function parameters did not differ. 13 non-pregnant and 8 pregnant asthmatic patients 
received ICS treatment, while 6 patients were steroid-naïve in both asthmatic groups. Steroid-
naïve and steroid-treated patients differed in none of the investigated parameters (such as 
spirometry results, ACT total scores, inflammatory parameters, peripheral eosinophil cell 
percentage). Mean ACT total score of 21.65 (±3.39) in the ANP and 20.18 (±4.12) in the AP 
group showed acceptable and similar level of disease control of the patients in both groups. 
Comparison of circulating marker levels among the four groups 
Treated and in most cases well-controlled asthma itself did not influence peripheral level of 
periostin, as it was similar in the HNP and ANP groups (55.68 [37.21-67.20] vs. 45.25 [32.67-
64.55], p > 0.05; Figure 1 A, Table 1). On the other hand, healthy pregnancy was associated with 
a marked elevation in periostin level (68.81 [57.34-98.84] ng/mL, p = 0.02 vs. HNP; Figure 1 A, 
Table 1). Similarly, this pregnancy-specific elevation was detectable also in the AP group (54.02 
[44.30-74.94] ng/mL, p = 0.03 vs. ANP) compared to the ANP group. There was no difference 
between the periostin levels of the two pregnant groups (p > 0.05; Figure 1 A, Table 1). 
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Peripheral level of CRP was somewhat higher in the ANP and AP groups compared to the HNP 
controls (4.0 [3.0-5.5] and 6.0 [3.0-6.5] vs. 3.0 [1.3-3.0] mg/L, respectively, p < 0.001; Figure 1 
B, Table 1); the two asthmatic groups did not differ. CRP was not measured in the HP group. 
We measured peripheral IL-6 levels only in the two asthmatic groups with the result that it was 
lower in the AP group compared with the ANP one (1.93 [1.50-3.34] vs. 4.21 [1.89-6.95] pg/mL, 
p = 0.04; Figure 1 C, Table 1). 
Peripheral percentage of eosinophil granulocytes was higher in the ANP and AP groups 
compared to the HP group (2.51 [2.09-4.30] and 2.26 [1.37-4.16] vs. 0.88 [0.50-1.00] %, 
respectively, p < 0.001) but not to the HNP one (1.55 [1.26-2.02] %, p > 0.05; Figure 1 D, Table 
1). 
Peripheral periostin concentration was not related to CRP or IL-6 levels in any study group; 
however, it showed a trend towards a correlation with peripheral eosinophil percentage in AP 
women (r = 0.47, p = 0.09). Furthermore, periostin tended to be higher in the AP participants 
who showed peripheral eosinophilia (as defined by >3% of peripheral white blood cells) 
compared to ones who did not show eosinophilia but the difference reached only the level of a 
trend (51.71 [41.45-69.54], n = 9 vs. 82.39 [49.76-87.24] ng/mL, n = 5, p = 0.09). In the ANP 
group, peripheral eosinophil percentage correlated with IL-6 levels (r = 0.53; p = 0.03). 
Relationship of inflammatory markers to asthma control determinants 
Circulating peripheral periostin level was significantly related to lung function in the AP group: 
it correlated negatively with forced expiratory volume in 1 second (FEV1; r = -0.55; Figure 2 A), 
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and positively with airway resistance (Raw; r = 0.55; Figure 2 B; both p < 0.05), while in the case 
of FVC the negative association reached only the level of a trend (r = -0.51, p = 0.06). On the 
other hand, all of these correlations were missing in the ANP group. Periostin levels were not 
related to ACT total scores or the dose of the prescribed ICS treatment either in the ANP or in 
the AP group. 
Peripheral eosinophil percentage correlated negatively with FEV1 in the ANP group (r = -0.53; 
Figure 3; p = 0.03). However in the AP group peripheral eosinophil percentage showed only a 
trend towards a negative correlation with FEV1 (r = -0.52, p = 0.05) and with PEF values (r = -
0.49, p = 0.09). 
In order to evaluate the efficacy of periostin measurement in the detection of uncontrolled 
asthma, ROC analyses of periostin data were performed in subgroups of AP and ANP patients 
with PEF above and below 80% and ACT total score above and below 20, as the current GINA 
guideline suggests these cut-off values to differentiate between optimal and suboptimal asthma 
control. None of these investigations yielded significant results. ROC analyses of CRP and IL-6 
values were performed also without significant results in any group. 
Relationship of inflammatory and functional parameters to obstetrical data 
Periostin concentrations were not related to gestational age at sampling either in the AP or in the 
HP group (p > 0.05). There was also no difference between periostin values of women in early 
pregnancy (first and second trimester) and women in late pregnancy (third trimester) neither in 
the AP nor in the HP group (p > 0.05). 
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We could not detect any association between periostin, CRP or IL-6 levels and obstetrical data 
such as gestational age at delivery and fetal birth weight. 
Discussion 
Periostin recently became a promising biomarker of Th2-driven airway inflammation and airway 
eosinophilia in asthma; however, its circulating level has not been examined in asthmatic 
pregnancy yet. In our study, we measured the peripheral levels of periostin in healthy and 
asthmatic pregnancy together with healthy and asthmatic non-pregnant patients. We 
demonstrated a marked increase in its level in pregnancy independently of concomitant asthma, 
as circulating periostin level was increased both in healthy and asthmatic pregnant, compared to 
healthy and asthmatic non-pregnant women, respectively. Unexpectedly, similar periostin levels 
were detected in mostly treated, controlled asthmatic non-pregnant patients and healthy controls; 
similarly, treated asthmatic and healthy pregnant women had similar periostin levels as well. On 
the other hand, in asthmatic pregnancy circulating periostin level correlated with worse lung 
function parameters. 
Circulating and tissue periostin levels change during pregnancy but its precise role is not fully 
elucidated in healthy or pathologic pregnancies. Circulating periostin level was shown to be 
increased in healthy pregnancy compared with non-pregnant volunteers [36, 37]. In line with 
this, we measured higher plasma levels in the HP group than in the HNP control group. In AP we 
found that the pregnancy induced elevation of circulating periostin level was present (compared 
to non-pregnant patients) suggesting that asthmatic processes do not interfere with the role of 
periostin in normal gestation. However, due to this pregnancy induced elevation, the value of 
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periostin as an asthma biomarker during pregnancy may be compromised. Moreover, potentially 
altered cut-off values are warranted compared to non-pregnant patients. In line with earlier 
results [37], periostin concentrations did not show any correlation with birth weight of the infants 
either in HP or in AP group in our study. 
Maintaining optimal disease control is a crucial need in asthmatic pregnancy, however both the 
value and the safety of spirometry may be challenged. Therefore, measurement of validated non-
invasive biomarkers such as periostin may represent an aid in risk assessment and asthma control 
evaluation in this problematic patient group. However, as periostin plays an important role in 
normal gestation and its level changes both in healthy and complicated pregnancies, its value as 
an asthma biomarker may be challenged during asthmatic pregnancy. Our study was the first to 
detect higher periostin levels in asthmatic gestation compared to non-pregnant patients. 
Furthermore, according to our data, in asthmatic pregnancy periostin concentrations were 
inversely associated with FEV1, and positively with Raw; these correlations were absent in the 
ANP group. The explanation of this discrepancy between the asthmatic groups may be the 
somewhat differing clinical state of the patients, as PEF and FVC values (expressed as 
percentage of predicted) were lower in the pregnant than in the non-pregnant patients in our 
study. Notably, according to earlier results, these two lung function parameters are expected to 
increase in healthy pregnant women compared to the non-pregnant state; hence in our pregnant 
asthmatic patients these lung function results have to be regarded as actually worse than they 
would seem to be in non-pregnant conditions [7] and thus the association between periostin and 
worse lung function may be more obvious in this group. Optimal lung function and well-
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controlled clinical state could mask the associations between periostin and lung function 
parameters in the ANP group. 
In our study we could not confirm the previous data [20, 39] as we did not detect higher 
peripheral periostin levels in bronchial asthma (without pregnancy) than in healthy controls. Of 
note, normal circulating levels of periostin or cut-off values in asthma are not defined yet and 
different values were considered as elevated in the different studies [20, 21, 22, 24, 39]. In the 
study by Jia et al. [21] the median serum level was as low as 24.5 (19.6-30.6) ng/mL in severe 
uncontrolled, treated asthmatic patients, while the average asthmatic serum level was 92.8 (± 
38.4) ng/mL found by Kanemitsu et al. [20] and 76.5 (± 35.2) ng/mL found by Kim et al. [39], 
both examining more heterogeneous, smoking and co-morbid populations. In Kim’s study [39] a 
cut-off value of 54.5 ng/mL discriminated asthmatic patients from healthy controls, with 71.8% 
sensitivity and 63.2% specificity (AUC = 0.75, p < 0.001). Our results are in line with these with 
a median value of 45.25 (32.67-64.55) ng/mL in the ANP group and 54.02 (44.30-74.94) in the 
AP group. Notably, in our study the disease was mainly well controlled and smoking was among 
the exclusion criteria in order to exclude the presence of COPD. In the ANP group the lung 
function of the patients was very good and asthma control was satisfactory. 
We detected higher peripheral eosinophil percentage in both asthmatic groups, but there was no 
statistically significant difference (only a weak trend) between eosinophilic and non-eosinophilic 
pregnant patients regarding their periostin level. The previously reported correlation between 
periostin concentration and peripheral eosinophil percentage [20, 39] was detected as a trend in 
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the pregnant asthmatic group in our study. In line with earlier results [40], peripheral eosinophil 
percentage correlated negatively with FEV1 in both asthmatic groups. 
Similarly to an earlier study [11] we measured peripheral CRP and IL-6 levels also, in order to 
have a more complete view on the inflammatory status of the patients. We observed slightly but 
clinically not relevantly elevated CRP levels in both asthmatic groups. Finally, IL-6 level was 
lower in the AP than in the ANP group, while in the earlier study IL-6 levels were comparable 
[11]. Lower IL-6 levels in AP women may be ascribed to pregnancy specific immune tolerance. 
Limitations 
The results should be interpreted with concern because there are several limitations of the study. 
The main limitation is the small sample size; however it is difficult to involve a large number of 
asthmatic pregnant women without comorbidities, concomitant medications, and without any 
known pregnancy complications. Our study had was designed to have a power of 80% to detect 
50% difference among the 4 groups; however it must be noted, that because of the large 
dispersion in the periostin data published in previous articles (for example median values of 24.5 
and 92.8 ng/mL), a priori power analysis may have carried some biases. Furthermore, the 
findings may differ in patients with severe asthma as the subjects in our study were mainly well 
controlled. Another limitation of the study is that lung function and asthma control data of some 
patients are missing (lung function in one AP, ACT in 2 ANP and 3 AP patients). Active 
smoking occurs in asthma including during pregnancy. As current smoking is reported to 
influence serum periostin concentrations [41], the circulating periostin concentrations may differ 
in asthmatic smokers during pregnancy. We compared our periostin data measured in plasma 
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from EDTA samples to studies evaluating periostin in sera; however periostin levels have been 
earlier shown to be comparable within subjects within assay limits independently of matrix and 
anticoagulant (serum, plasma anticoagulated with EDTA, plasma anticoagulated with sodium 
citrate, and plasma anticoagulated with heparin) [21]. 
Conclusions 
According to the data of this low sample-size study, pregnancy itself markedly increases 
circulating periostin levels, and this elevation is detectable both in healthy and asthmatic women. 
Hence, circulating periostin level in asthmatic and healthy pregnancy is similar. Although 
periostin correlates with lung function in asthmatic pregnancy, periostin as a biomarker has to be 
handled with caution in pregnant patients due to the influence of pregnancy on its plasma level. 
Further longitudinal studies with larger sample sizes would be warranted to show whether 
periostin is a suitable tool in phenotyping, control evaluation, or decision-making process during 
asthmatic pregnancy. 
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Table 1. Clinical data and inflammatory parameters of the four study groups (mean±SD, 
median [interquartile range]). 
 
 HNP(n = 12) HP(n = 17) ANP(n = 19) AP(n = 14) 
Age (years) 31.4±6.9 34.8±3.2
n = 15
 35.0±6.3 31.1±6.2 
Gestational age 
at sampling 
(weeks) 
- 29.0±10.9 - 27.3±8.3 
1. / 2. / 3. 
trimester 
- 3 / 2 / 12 - 1 / 4 / 9 
Gestational age 
at delivery 
(weeks) 
- 38.5±1.9
n = 14
 - 37.9±1.4
n = 8
 
Fetal birth 
weight (grams) 
- 3309±458.0
n = 14
 - 3023±502.8
n = 8
 
FEV1 (% of 
predicted) 
- - 98.3±15.1
n = 18
 88.5±13.9 
FVC (% of - - 108.3±11.6
n = 18
 95.5±10.3
c
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predicted) 
PEF (% of 
predicted) 
- - 90.9±13.9
n = 18
 77.9±15.8
n = 13, c
 
Raw - - 0.29±0.15
n = 18
 0.32±0.19 
FEF25-75% (% of 
predicted) 
- - 80.5±25.2
n = 18
 76.50±27.9
n = 12
 
ACT total score - - 21.65±3.39
n = 17
 20.18±4.12
n = 11
 
Daily dose of 
ICS 
(beclomethasone 
equivalent, μg) 
- - 800 (0- 1000)
n = 18
 650 (0- 1000) 
Steroid-naïve / 
steroid-treated 
patients 
- - 6 / 13 6 / 8 
Eosinophil cells 
(%) 
1.55 [1.26-
2.02] 
0.88 [0.50-1.00]
n = 
7
 
2.51 [2.09-4.30]
n = 
18, b
 
2.26 [1.37-4.16]
b
 
CRP (mg/L) 3.0 [1.3-3.0]
 n 
= 11
 
- 4.0 [3.0-5.5]
n = 17, a
 6.0 [3.0-6.5]
n = 13, 
a
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IL-6 (pg/mL) - - 4.21 [1.89-6.95]
n = 
17
 
1.93 [1.50-3.34]
n 
= 13, c
 
Periostin 
(ng/mL) 
55.68 [37.21-
67.20] 
68.81 [57.34-
98.84]
a
 
45.25 [32.67-
64.55]
b
 
54.02 [44.30-
74.94]
c
 
HNP -- healthy non-pregnant; HP -- healthy pregnant; ANP -- asthmatic non-pregnant; AP -- 
asthmatic pregnant; FEV1 -- forced expiratory volume in 1 second; FVC -- forced vital capacity; 
PEF -- peak expiratory flow rate; Raw -- airway resistance; FEF25-75% -- forced expiratory flow at 
25--75% of forced vital capacity; ACT -- asthma control test; ICS -- inhaled corticosteroid; CRP 
-- C-reactive protein; IL-6 -- interleukin 6; 
a
 p < 0.05 vs. HNP, 
b
 p < 0.05 vs. HP, 
c
 p < 0.05 vs. 
ANP. 
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Figure 1. Circulating periostin (A), CRP (B), IL-6 (C) levels and peripheral eosinophil cell 
percentage (D) measured in healthy non-pregnant and pregnant, and asthmatic non-
pregnant and pregnant subjects. HNP -- healthy non-pregnant; HP -- healthy pregnant; ANP -- 
asthmatic non-pregnant; AP -- asthmatic pregnant; CRP -- C-reactive protein; IL-6 -- interleukin 
6; 
a
 p < 0.05 vs. HNP, 
b
 p < 0.05 vs. HP, 
c
 p < 0.05 vs. ANP. 
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Figure 2. Negative correlation of circulating periostin to FEV1 (A) and positive correlation 
of circulating periostin to airway resistance (Raw) (B) in asthmatic pregnant patients, and 
lack of these correlations (C, D) in asthmatic non-pregnant patients FEV1 -- forced 
expiratory volume in 1 second; Raw -- airway resistance. 
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Figure 3. Negative correlation of peripheral eosinophil cell percentage to FEV1 in asthmatic 
non-pregnant patients. FEV1 -- forced expiratory volume in 1 second. 
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